Thus, we calculated the risk score of each MM patients, and built the 9 hub genes [HLA-DPB1(major histocompatibility complex, class II, DP beta 1), TOP2A (topoisomerase 2A), FABP5 (Fatty Acid-Binding Protein 5), CYP1B1(cytochrome P450 family 1 subfamily B member 1), IGHM (immunoglobulin heavy constant mu), FANCI (FA complementation group I), LYZ (lysozyme), HMGN5 (high mobility group protein N5 subtype), and BEND6 (BEN domain containing 6)] based signature. This evidence concerns the gene LYZ and Miyoshi myopathy.